A Phase 2/3 interventional study of RO7204239 and Placebo in Spinal Muscular Atrophy (SMA), sponsored by Hoffmann-La Roche. Completed at 29 sites in 12 countries. Open to participants aged 2 Years to 25 Years. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Hoffmann-La Roche · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Muscular Atrophy, Spinal by Hoffmann-La Roche — 1 open to participants now, 4 under way, none of them phase 3. Muscular Atrophy, Spinal · Hoffmann-La Roche.
Among the 18 studies in Muscular Atrophy, Spinal by Hoffmann-La Roche, this one is the 6th largest by enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2022, is the only one in phase 2/3, and was the 13th registered.
282 studies on the registry are indexed under Muscular Atrophy, Spinal; 72 are open to participants now.
Browse Muscular Atrophy, Spinal studies →1 of the 18 studies in Muscular Atrophy, Spinal by Hoffmann-La Roche is open now, in 1 country. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in Egypt
Ages up to 5
By country, each count listing its studies:
Of the 57 Muscular Atrophy, Spinal studies recruiting now, 28 (49%) set no upper age limit and 26 (46%) stop at 75 or younger; 45 take children under 18; 11 take healthy volunteers.
This study: 2 Years to 25 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 7 · Phase 3 1 · Phase 4 3
First in 2013; this study’s year is marked. 2 started in 2022.
This study's enrollment of 97 is above the median of 29 across 156 interventional studies indexed under Muscular Atrophy, Spinal.
Median enrollment 35 across the 15 interventional studies, 33 across the 2 observational. Of the 13 that completed or were terminated, 6 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 18 studies in Muscular Atrophy, Spinal by Hoffmann-La Roche, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Risdiplam works by helping the body produce more survival motor neuron (SMN) protein throughout the body. This means fewer motor neurons - nerve cells that pass impulses from nerves to muscles to cause movement - are lost, which may improve how well muscles work in people with SMA. RO7204239 is an investigational anti-myostatin antibody that is designed to target myostatin. Myostatin plays an important role in the regulation of skeletal muscle size by controlling growth. Inhibiting myostatin may help muscles grow in size and strength. RO7204239 in combination with risdiplam, which is designed to increase the amount of SMN protein throughout the body, has the potential to further improve motor function and clinical outcomes for people living with SMA.
This trial will study the safety and efficacy of RO7204239 in combination with risdiplam in patients with spinal muscular atrophy (SMA). The trial has two parts; Part 1 is the dose-finding part in SMA patients that are either ambulant (aged 2-10 years) or non-ambulant (aged 5-10 years) within separate cohorts, and Part 2 is the pivotal part in SMA patients aged 2-25 years that are ambulant.
Inclusion Criteria:
Inclusion Criteria for Part 1 Cohorts A, B, and C and Part 2 only:
Inclusion Criteria for Part 1 Cohort D only:
Exclusion Criteria:
Exclusion Criteria for Part 1 Cohorts A and B only:
Exclusion Criteria for Part 1 Cohort D only:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who have not previously been treated with risdiplam will receive risdiplam for at least 8 weeks prior to randomization into a treatment group (Part 1 only). Participants that have been treated with risdiplam for at least 8 continuous weeks immediately prior to joining the study may be immediately randomized to combination therapy, or join the study run-in period (the period between screening and randomization to a treatment group) where they will continue to receive risdiplam monotherapy until randomization. Participants enrolled in Part 1 will receive RO7204239 (low or high dose) + risdiplam for 24 weeks, followed by RO7204239 + risdiplam for 72 weeks. Participants enrolled in Part 2 will receive risdiplam for 8 weeks and then treatment with RO7204239 + risdiplam for 72 weeks. Once the treatment period has completed (Part 1 or Part 2), participants will have the option of treatment with RO7204239 + risdiplam for 2 additional years.
Drug: RO7204239 · Drug: Risdiplam
Participants who have not previously been treated with risdiplam will receive risdiplam for at least 8 weeks prior to randomization into a treatment group (Part 1 only). Participants that have been treated with risdiplam for at least 8 continuous weeks immediately prior to joining the study may be immediately randomized to combination therapy, or join the study run-in period (the period between screening and randomization to a treatment group) where they will continue to receive risdiplam monotherapy until randomization. Participants enrolled in Part 1 will receive placebo (low or high dose-matched) + risdiplam for 24 weeks, followed by RO7204239 + risdiplam for 72 weeks. Participants enrolled in Part 2 will receive risdiplam for 8 weeks and then treatment with placebo + risdiplam for 72 weeks. Once the treatment period has completed (Part 1 or Part 2), participants will have the option of treatment with RO7204239 + risdiplam for 2 additional years.
Drug: Placebo · Drug: Risdiplam
RO7204239 will administered every 4 weeks (Q4W) by subcutaneous (SC) injection into the abdomen. RO7204239 will be investigated at low- and high-dose in Part 1.
Placebo will be administered Q4W by SC injection into the abdomen.
Risdiplam will be administered orally once daily (QD) for the duration of the study.
Also known as: RO7034067, Evrysdi
Part 1 - Percentage of participants with adverse events (AEs)
Time frame: Up to 4.5 years
Part 1 - Incidence of relevant echocardiographic parameter z scores > 2
Time frame: Up to 4.5 years
Part 1 - Serum concentration of RO7204239
Time frame: Through Week 96
Part 1 - Time to maximum serum concentration (Cmax) of RO7204239
Time frame: Through Week 96
Part 1 - Area under the curve (AUC) of RO7204239
Time frame: Through Week 96
Part 1 - Trough concentration (Ctrough) of RO7204239
Time frame: Through Week 96
Part 1 - Plasma concentration of risdiplam
Time frame: Week 21
Part 1 - Plasma concentration of risdiplam metabolite (M1)
Time frame: Week 21
Part 1 - Cmax of risdiplam
Time frame: Week 21
Part 1 - AUC of risdiplam
Time frame: Week 21
Part 1 - Ctrough of risdiplam
Time frame: Week 21
Part 1 - Incidence of anti-drug antibodies (ADAs)
Time frame: Through Week 96
Part 1 - Change from baseline in serum concentration of total myostatin
Time frame: Through Week 85
Part 1 - Change from baseline in serum concentration of free latent myostatin
Time frame: Through Week 85
Part 1 - Change from baseline in serum concentration of mature myostatin
Time frame: Through Week 85
Part 1 - Percent change from baseline in the contractile area of skeletal muscle in the dominant thigh muscles as assessed by magnetic resonance imaging (MRI) in participants aged at least 5 years
Time frame: Week 24 of combination treatment
Part 1 - Percent change from baseline in the contractile area of skeletal muscle in the dominant calf muscles as assessed by MRI in participants aged at least 5 years
Time frame: Week 24 of combination treatment
Part 2 - Change from baseline in Revised Hammersmith Scale (RHS) total score
Time frame: Week 72 of combination treatment (study Week 80)
Part 2 - Change from baseline in Motor Function Measure (MFM) Domain 1 + Domain 2 (D1 + D2) score
Time frame: Week 72 of combination treatment (study Week 80)
Part 2 - Change from baseline in MFM-32 total score
Time frame: Week 72 of combination treatment (study Week 80)
Part 2 - Change from baseline in time taken to rise from the floor as measured by RHS Item 25
Time frame: Week 72 of combination treatment (study Week 80)
Part 2 - Change from baseline in time taken to walk/run 10 meters as measured by RHS Item 19
Time frame: Week 72 of combination treatment (study Week 80)
Part 2 - Percent change from baseline in lean mass as assessed by full body dual energy X-ray absorptiometry (DXA) scan in participants aged at least 5 years
Time frame: Week 72 of combination treatment (study Week 80)
Part 2 - Percentage of participants with adverse events (AEs)
Time frame: Up to 4.5 years
Part 2 - Serum concentration of RO7204239
Time frame: Through Week 80
Part 2 - Cmax of RO7204239
Time frame: Through Week 80
Part 2 - AUC of RO7204239
Time frame: Through Week 80
Part 2 - Ctrough of RO7204239
Time frame: Through Week 80
Part 2 - Plasma concentration of risdiplam
Time frame: Week 32
Part 2 - Plasma concentration of risdiplam metabolite (M1)
Time frame: Week 32
Part 2 - Cmax of risdiplam
Time frame: Week 32
Part 2 - AUC of risdiplam
Time frame: Week 32
Part 2 - Ctrough of risdiplam
Time frame: Week 32
Part 2 - Incidence of ADAs
Time frame: Through Week 80
Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
No publications or documents are linked to this record.
Ran from Jun 2022 to primary completion in Nov 2026, 53 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: primary completion Oct 2026 → Nov 2026 and completion Oct 2026 → Nov 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Emugrobart